stockrowMyriad Genetics, Inc. (MYGN) vs Exagen Inc. (XGN)
- Myriad Genetics, Inc. MYGN 6.19 +2.82%
- Exagen Inc. XGN 7.52 −11.63%
Myriad Genetics, Inc. and Exagen Inc. are both Diagnostics & Research companies. Myriad Genetics, Inc. is the larger, with a market value of $601.6M against $184.1M — 3.3× the size. Exagen Inc. grew revenue faster over the last twelve months: 20.8% against −3.16%. Myriad Genetics, Inc. has the higher net margin (−14.0% vs −26.6%) and the higher return on invested capital (−19.9% vs −68.3%). Across the 18 metrics below, Myriad Genetics, Inc. leads on 12 and Exagen Inc. on 6.
Valuation
Profitability
| Metric | MYGN | XGN | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 68.83% | 58.64% | 48.32% |
| Operating margin | (12.22%) | (18.58%) | (5.68%) |
| Net margin | (13.96%) | (26.61%) | (4.10%) |
| Free cash flow margin | (1.76%) | (10.66%) | 0.00% |
| Return on equity | (32.54%) | (113.82%) | 0.00% |
| Return on assets | (17.11%) | (34.19%) | (6.05%) |
| Return on invested capital | (19.92%) | (68.33%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack